Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

被引:458
作者
Carew, Jennifer S. [1 ]
Giles, Francis J. [1 ]
Nawrocki, Steffan T. [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78245 USA
关键词
historic deacetylase inhibitor; apoptosis; autophagy; bortezomib; TRAIL;
D O I
10.1016/j.canlet.2008.03.037
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Histone deacetylases (HDACs) play an important role in the epigenetic regulation of gene expression by catalyzing the removal of acetyl groups, stimulating chromatin condensation and promoting transcriptional repression. Since aberrant epigenetic changes are a hallmark of cancer, HDACs are a promising target for pharmacological inhibition. HDAC inhibitors can induce cell-cycle arrest, promote differentiation, and stimulate tumor cell death. These properties have prompted numerous preclinical and clinical investigations evaluating the potential efficacy of HDAC inhibitors for a variety of malignancies. The preferential toxicity of HDAC inhibitors in transformed cells and their ability to synergistically enhance the anticancer activity of many chemotherapeutic agents has further generated interest in this novel class of drugs. Here we summarize the different mechanisms of HDAC inhibitor-induced apoptosis and discuss their use in combination with other anticancer agents. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:7 / 17
页数:11
相关论文
共 73 条
[1]
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells [J].
Adachi, M ;
Zhang, YB ;
Zhao, XD ;
Minami, T ;
Kawamura, R ;
Hinoda, Y ;
Imai, K .
CLINICAL CANCER RESEARCH, 2004, 10 (11) :3853-3862
[2]
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma [J].
Amaravadi, Ravi K. ;
Yu, Duonan ;
Lum, Julian J. ;
Bui, Thi ;
Christophorou, Maria A. ;
Evan, Gerard I. ;
Thomas-Tikhonenko, Andrei ;
Thompson, Craig B. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (02) :326-336
[3]
p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells [J].
Archer, SY ;
Meng, SF ;
Shei, A ;
Hodin, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (12) :6791-6796
[4]
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer [J].
Arnold, Nichole Boyer ;
Arkus, Nolhea ;
Gunn, Jason ;
Korc, Murray .
CLINICAL CANCER RESEARCH, 2007, 13 (01) :18-26
[5]
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3 [J].
Bali, P ;
George, P ;
Cohen, P ;
Tao, JG ;
Guo, F ;
Sigua, C ;
Vishvanath, A ;
Scuto, A ;
Annavarapu, S ;
Fiskus, W ;
Moscinski, L ;
Atadja, P ;
Bhalla, K .
CLINICAL CANCER RESEARCH, 2004, 10 (15) :4991-4997
[6]
Anticancer activities of histone deacetylase inhibitors [J].
Bolden, Jessica E. ;
Peart, Melissa J. ;
Johnstone, Ricky W. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784
[7]
HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates [J].
Boyault, Cyril ;
Zhang, Yu ;
Fritah, Sabrina ;
Caron, Cecile ;
Gilquin, Benoit ;
Kwon, So Hee ;
Garrido, Carmen ;
Yao, Tso-Pang ;
Vourc'h, Claire ;
Matthias, Patrick ;
Khochbin, Saadi .
GENES & DEVELOPMENT, 2007, 21 (17) :2172-2181
[8]
Burgess AJ, 2001, MOL PHARMACOL, V60, P828
[9]
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin [J].
Butler, LM ;
Zhou, XB ;
Xu, WS ;
Scher, HI ;
Rifkind, RA ;
Marks, PA ;
Richon, VM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (18) :11700-11705
[10]
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J].
Cameron, EE ;
Bachman, KE ;
Myöhänen, S ;
Herman, JG ;
Baylin, SB .
NATURE GENETICS, 1999, 21 (01) :103-107